Form 4: Shattuck Labs Chief Business Officer Reports Stock Transactions

Casi DeYoung, Chief Business Officer of Shattuck Labs, reports the acquisition of stock options and the disposal of shares to cover tax obligations.

Summary

• Casi DeYoung, the Chief Business Officer of Shattuck Labs, filed a Form 4 detailing recent transactions involving the company's stock.
• On January 25, 2025, DeYoung disposed of 2,297 shares of common stock at a price of $1.16 per share.
• This disposal was likely to cover tax obligations related to the vesting of stock options.
• On January 28, 2025, DeYoung acquired options to purchase 194,300 shares of common stock at an exercise price of $1.18 per share.
• These options vest over time, with one quarter vesting on January 28, 2026, and the remaining three quarters vesting monthly through January 28, 2029, contingent on continued service.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of options is a positive sign, but the disposal of shares is a neutral event, likely for tax purposes. Overall, it's a routine filing.

Positives

• The acquisition of 194,300 stock options by a key executive signals confidence in the company's future.

Negatives

• The disposal of 2,297 shares, while likely for tax purposes, could be perceived negatively by some investors.

Risks

• The vesting of the options is contingent on continued service, which introduces a risk of forfeiture if the executive leaves the company.
• The market price of the stock could fluctuate, impacting the value of the options.

Future Outlook

The document does not contain any specific forward-looking statements about the company's future performance, but the vesting schedule of the options indicates a long-term commitment from the executive.

Management Comments

• There are no direct quotes from management in this document, but the filing of the Form 4 indicates compliance with SEC regulations.

Industry Context

This filing is a routine disclosure of insider transactions, which is common in the biotechnology industry. It provides transparency into the stock ownership of key executives.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies, particularly in the biotech sector where stock options are a common form of compensation.
• The vesting schedule of the options is typical for executive compensation packages, designed to align the executive's interests with the long-term performance of the company.
• Comparable companies in the biotech space also regularly report similar transactions by their executives.

Stakeholder Impact

• Shareholders may view the acquisition of options as a positive sign of executive confidence.
• The disposal of shares is unlikely to have a significant impact on stakeholders.

Next Steps

• The executive will continue to vest in the stock options over the next few years, contingent on continued service.

Key Dates

Keywords

Shattuck Labs, stock options, Form 4, insider trading, executive compensation, Casi DeYoung, stock disposal, share acquisition